Pfizer Highlights Launches, Late-State Pipeline To Distract From Sluggish Earnings
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Ian Read admitted tax inversion remains an attractive potential deal-driver for now, though he declined to offer much insight into the company’s near-term M&A strategy.